Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CIML NK Cells + FLAG in Pediatric Relapsed/Refractory AML
NCT04354025Phase 2Withdrawn
- Sponsor
- Washington University School of Medicine
- Start
- Jun 2023
- Primary completion
- Sep 2026
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Lymphokine-Activated Killer Cells
01
Overview
A Phase 2 trial of cytokine-induced memory-like natural killer cells in acute myeloid leukemia (AML), sponsored by Washington University School of Medicine. Planned start Jun 2023; status: withdrawn.
02
Drugs
cytokine-induced memory-like natural killer cells
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04354025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04354025.